Ocumetics Closes First Tranche of Private Placement

Calgary, AB — January 2, 2026 — Leads & Copy — Ocumetics Technology Corp. has closed the first tranche of its brokered private placement of units, raising approximately $788,380. The company also closed a concurrent non-brokered private placement, raising an additional $235,450.

The offerings were led by Centurion One Capital Corp., serving as the lead agent for the brokered offering and fiscal advisor for the non-brokered offering. Tingle Merrett LLP and Cassels Brock & Blackwell LLP provided legal counsel to Ocumetics and Centurion One Capital Corp., respectively.

A total of 1,706,383 units were sold at $0.60 per unit, resulting in gross proceeds of approximately $1,023,830. Each unit includes one common share and one common share purchase warrant. The warrant allows the holder to purchase an additional common share at $0.75 until December 30, 2028.

Ocumetics plans to use the proceeds from the offerings to fund its first-in-human clinical trials, ongoing research and development, and for general corporate purposes. The actual allocation of proceeds may vary depending on future operations, events, or opportunities.

In connection with the offerings, the company paid $143,336.17 in commissions, fees, and advisory fees, with $61,429.79 paid through the issuance of 102,382 units. Ocumetics also issued 136,510 common share purchase warrants, each allowing the holder to acquire one unit at the issue price until December 30, 2028. The Lead Agent intends to close the rest of the Offerings in one or more subsequent tranches.

The units were offered via private placement under the listed issuer financing exemption and available exemptions from the U.S. Securities Act of 1933. Securities issued under the listed issuer financing exemption will not be subject to a statutory hold period.

Certain directors of Ocumetics participated in the private placement, making it a “Related Party Transaction” under Multilateral Instrument 61-101. The company relied on exemptions from minority shareholder approval and valuation requirements. The directors unanimously approved the private placement.

Ocumetics Technology Corp. is dedicated to developing advanced vision correction solutions. It focuses on intraocular lenses designed to eliminate the need for corrective lenses by allowing the eye to naturally shift focus.

Dean Burns, President and CEO, can be reached at 817-874-7564.

Source: Ocumetics Technology Corp.